Get access to our best features
Get access to our best features
Published

NMPA expands approval to MSD’s GARDASIL for use in males

Summary by Pharmaceutical-technology.com
China's National Medical Products Administration has granted expanded approval to MSD's GARDASIL for use in males aged nine to 26 years.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)